retatrutide clinical trials latest A new trial from Eli Lilly and Company suggests its experimental triple hormone drug, retatrutide, could become one of the next major medications in the rapidly growing weight loss and diabetes retatrutide clinical trials latest New

The longer answer depends on which clinical trial data you reference, your prior experience with GLP-1 agonists, and your individual tolerance profile

Dehydration makes nausea significantly worse For diarrhea: Increase fiber intake gradually, not suddenly Stay hydrated with electrolyte solutions, not just plain water Avoid sugar alcohols and artificial sweeteners, which can worsen GI symptoms For constipation: Increase water intake to at least 2-3 liters daily Add magnesium citrate if needed (a gentle, effective option) Include high-fiber vegetables and fruits in your diet When to slow the escalation If you experience side effects that significantly impact your daily function, extend the current dose phase by 2-4 additional weeks before escalating

In Phase 2 obesity trials, retatrutide produced approximately 24% mean body-weight reduction at 48 weeks at the 12 mg dose the largest weight-loss effect reported for any GLP-1-class compound to date

Cell Rep 2016

Safety: What Are the Risks

Eficacia y seguridad para la obesidad revisin sistemtica y metaanlisis de ensayos controlados aleatorios PubMed Agonista triple de GLP-1, GIP y glucagn: revisin sistemtica PubMed Almacenamiento Manejo y estabilidad